Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation: A Prospective, Multicenter Cohort Study
By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).
• Recipients aged ≥18 years undergoing single or double lung transplantation;
• Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study;
• Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations;
• Recipients able to undergo dynamic pulmonary function monitoring during follow-up;
• No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function;
• Retransplant patients will be considered as a new transplant event and may be included in the analysis.